Additionally, studies from China suggested that liquid biopsy based on 5-hydroxymethylcytosine signatures of cfDNA may accurately distinguish HCC patients from healthy controls and high HCC risk patients [41,42], whereas the diagnostic accuracy can increase by combining other HCC biomarkers such as AFP and des-gamma-carboxy prothrombin [42]. This evidence concerns the gene AFP and hepatocellular carcinoma.